Overall, by breaking the vicious diabetes–kidney–heart cycle, the collective impact of SGLT2 inhibitors on heart and kidney function could explain why these agents may benefit all populations rather than only patients with T2DM. The gene discussed is SLC5A2; the disease is diabetes mellitus.